These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 26568595)

  • 1. Development of a Provisional Core Domain Set for Polymyalgia Rheumatica: Report from the OMERACT 12 Polymyalgia Rheumatica Working Group.
    Helliwell T; Brouwer E; Pease CT; Hughes R; Hill CL; Neill LM; Halls S; Simon LS; Mallen CD; Boers M; Kirwan JR; Mackie SL
    J Rheumatol; 2016 Jan; 43(1):182-6. PubMed ID: 26568595
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polymyalgia Rheumatica (PMR) Special Interest Group at OMERACT 11: outcomes of importance for patients with PMR.
    Mackie SL; Arat S; da Silva J; Duarte C; Halliday S; Hughes R; Morris M; Pease CT; Sherman JW; Simon LS; Walsh M; Westhovens R; Zakout S; Kirwan JR
    J Rheumatol; 2014 Apr; 41(4):819-23. PubMed ID: 24488422
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The OMERACT Core Domain Set for Outcome Measures for Clinical Trials in Polymyalgia Rheumatica.
    Mackie SL; Twohig H; Neill LM; Harrison E; Shea B; Black RJ; Kermani TA; Merkel PA; Mallen CD; Buttgereit F; Mukhtyar C; Simon LS; Hill CL;
    J Rheumatol; 2017 Oct; 44(10):1515-1521. PubMed ID: 28765246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcome Measures in Polymyalgia Rheumatica. A Systematic Review.
    Duarte C; Ferreira RJ; Mackie SL; Kirwan JR; Pereira da Silva JA;
    J Rheumatol; 2015 Dec; 42(12):2503-11. PubMed ID: 26568600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes Measured in Polymyalgia Rheumatica and Measurement Properties of Instruments Considered for the OMERACT Core Outcome Set: A Systematic Review.
    Twohig H; Owen C; Muller S; Mallen CD; Mitchell C; Hider S; Hill C; Shea B; Mackie SL
    J Rheumatol; 2021 Jun; 48(6):883-893. PubMed ID: 32739892
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Toward a Core Outcome Measurement Set for Polymyalgia Rheumatica: Report from the OMERACT 2018 Special Interest Group.
    Owen CE; Yates M; Twohig H; Muller S; Neill LM; Harrison E; Shea B; Simon LS; Hill CL; Mackie SL
    J Rheumatol; 2019 Oct; 46(10):1360-1364. PubMed ID: 30709960
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of polymyalgia rheumatica: a systematic review.
    Hernández-Rodríguez J; Cid MC; López-Soto A; Espigol-Frigolé G; Bosch X
    Arch Intern Med; 2009 Nov; 169(20):1839-50. PubMed ID: 19901135
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term glucocorticoid treatment in patients with polymyalgia rheumatica, giant cell arteritis, or both diseases: results from a national rheumatology database.
    Albrecht K; Huscher D; Buttgereit F; Aringer M; Hoese G; Ochs W; Thiele K; Zink A
    Rheumatol Int; 2018 Apr; 38(4):569-577. PubMed ID: 29124397
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Perspectives and unmet needs in polymyalgia rheumatica. Providing the fundamental framework for the development of new treatment regimes in polymyalgia rheumatica.
    Nielsen BD; Dasgupta B
    Reumatismo; 2018 Mar; 70(1):1-9. PubMed ID: 29589397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exploring the patient experience in polymyalgia rheumatica.
    Harris GK; Leung JL; Buchanan RRC
    Clin Rheumatol; 2023 Dec; 42(12):3421-3422. PubMed ID: 37861872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polymyalgia Rheumatica and Giant Cell Arteritis: A Systematic Review.
    Buttgereit F; Dejaco C; Matteson EL; Dasgupta B
    JAMA; 2016 Jun; 315(22):2442-58. PubMed ID: 27299619
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of outcome domains in immune checkpoint inhibitor-induced inflammatory arthritis and polymyalgia rheumatica: A scoping review by the OMERACT irAE working group.
    Ghosh N; Couette N; van Binsbergen WH; Weinmann SC; Jivanelli B; Shea B; Bass AR; Benesova K; Bingham CO; Calabrese C; Cappelli LC; Chan KK; Choy E; Daoussis D; Goodman S; Hudson M; Jamal S; Leipe J; Lopez-Olivo MA; Suarez-Almazor M; van der Laken CJ; Meara AS; Liew D; Kostine M
    Semin Arthritis Rheum; 2023 Feb; 58():152110. PubMed ID: 36372016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Feasibility and Face Validity of Outcome Measures for Use in Future Studies of Polymyalgia Rheumatica: An OMERACT Study.
    Yates M; Owen CE; Muller S; Graham K; Neill L; Twohig H; Boers M; Pujades Rodriguez M; Goodman SM; Cheah J; Dejaco C; Mukhtyar C; Nielsen BD; Robson J; Simon LS; Shea B; Mackie SL; Hill CL;
    J Rheumatol; 2020 Sep; 47(9):1379-1384. PubMed ID: 32007937
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Consensus of the definitions of the OMERACT glucocorticoid impact core domain set for people with rheumatic and musculoskeletal diseases.
    Lyne SA; Yip K; Vasiliou VS; Katz DA; Richards P; Tieu J; Black RJ; Bridgewater S; Palmowski A; Beaton D; Maxwell LJ; Robson JC; Mackie SL; Goodman SM; Hill CL
    Semin Arthritis Rheum; 2024 Feb; 64():152338. PubMed ID: 38134623
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 1-year results of treatment with rituximab in polymyalgia rheumatica: an extension study of a randomised double-blind placebo-controlled trial.
    Bolhuis TE; Marsman DE; den Broeder AA; den Broeder N; van der Maas A
    Lancet Rheumatol; 2023 Apr; 5(4):e208-e214. PubMed ID: 38251523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Establishing a core domain set to measure rheumatoid arthritis flares: report of the OMERACT 11 RA flare Workshop.
    Bykerk VP; Lie E; Bartlett SJ; Alten R; Boonen A; Christensen R; Furst DE; Hewlett S; Leong AL; Lyddiatt A; March L; May JE; Montie P; Orbai AM; Pohl C; Scholte Voshaar M; Woodworth T; Bingham CO; Choy EH
    J Rheumatol; 2014 Apr; 41(4):799-809. PubMed ID: 24584927
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current evidence for therapeutic interventions and prognostic factors in polymyalgia rheumatica: a systematic literature review informing the 2015 European League Against Rheumatism/American College of Rheumatology recommendations for the management of polymyalgia rheumatica.
    Dejaco C; Singh YP; Perel P; Hutchings A; Camellino D; Mackie S; Matteson EL; Dasgupta B
    Ann Rheum Dis; 2015 Oct; 74(10):1808-17. PubMed ID: 26359489
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The real evidence for polymyalgia rheumatica as a paraneoplastic syndrome.
    Muller S; Hider S; Helliwell T; Partington R; Mallen C
    Reumatismo; 2018 Mar; 70(1):23-34. PubMed ID: 29589400
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polymyalgia rheumatica: strategies for efficient practice and quality assurance.
    Schirmer M; Dejaco C; Dasgupta B; Matteson EL
    Rheumatol Int; 2015 Nov; 35(11):1781-9. PubMed ID: 26032754
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of a Draft Core Set of Domains for Measuring Shared Decision Making in Osteoarthritis: An OMERACT Working Group on Shared Decision Making.
    Toupin-April K; Barton J; Fraenkel L; Li L; Grandpierre V; Guillemin F; Rader T; Stacey D; Légaré F; Jull J; Petkovic J; Scholte-Voshaar M; Welch V; Lyddiatt A; Hofstetter C; De Wit M; March L; Meade T; Christensen R; Gaujoux-Viala C; Suarez-Almazor ME; Boonen A; Pohl C; Martin R; Tugwell PS
    J Rheumatol; 2015 Dec; 42(12):2442-7. PubMed ID: 25877502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.